Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMDW) EBITDA (2019 - 2025)

Historic EBITDA for Revolution Medicines (RVMDW) over the last 7 years, with Q3 2025 value amounting to -$303.4 million.

  • Revolution Medicines' EBITDA fell 10143.81% to -$303.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 billion, marking a year-over-year decrease of 6538.39%. This contributed to the annual value of -$599.3 million for FY2024, which is 3807.76% down from last year.
  • As of Q3 2025, Revolution Medicines' EBITDA stood at -$303.4 million, which was down 10143.81% from -$264.7 million recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' EBITDA peaked at -$37.4 million during Q1 2021, and registered a low of -$303.4 million during Q3 2025.
  • Moreover, its 5-year median value for EBITDA was -$108.1 million (2023), whereas its average is -$123.8 million.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 1661.97% in 2022, then crashed by 15948.76% in 2023.
  • Quarter analysis of 5 years shows Revolution Medicines' EBITDA stood at -$52.9 million in 2021, then fell by 16.62% to -$61.7 million in 2022, then plummeted by 159.49% to -$160.1 million in 2023, then decreased by 23.07% to -$197.1 million in 2024, then crashed by 53.96% to -$303.4 million in 2025.
  • Its EBITDA stands at -$303.4 million for Q3 2025, versus -$264.7 million for Q2 2025 and -$240.8 million for Q1 2025.